Business Wire

I-Pulse Launches iTerra Pulsed Power Solution for Weed Control Without Chemicals

11.3.2026 14:30:00 CET | Business Wire | Press Release

Share

I-Pulse Co-Founder, Chairman, and CEO Robert Friedland, I-Pulse Co-Founder and Chief Technology Officer, Laurent Frescaline, and iTerra CEO, Romain Leray, are pleased to announce the launch of iTerra, an agricultural technology subsidiary dedicated to non-chemical weed control within I-Pulse, the world leader in pulsed power technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311080724/en/

iTerra leverages I-Pulse’s proprietary high pulsed power technology to eliminate weeds at the root without harming crops, disrupting soil microbiology, or leaving chemical residues. Using AI-driven detection with accuracy rates of up to 95% in early trials, the system targets each weed individually with controlled, high-energy pulses lasting just five milliseconds. The treated weeds remain in the soil, where they naturally decompose, helping maintain soil health and supporting long-term crop performance.

I-Pulse Co-Founder, Chairman and CEO Robert Friedland commented: “By controlling weeds with our pulsed electrical power, we will reduce reliance on the load of poisonous chemicals that are being used in global agriculture. It maintains soil health so that the food can be organic and regenerative by protecting the water table.”

iTerra will be overseen by I-Pulse’s leadership team, with iTerra CEO Romain Leray managing day-to-day operations. George Eustice, former UK Secretary of State for Environment, Food & Rural Affairs, and Sarah Mock, U.S. Agriculture Policy Analyst and former Washington Correspondent for RFD-TV, have joined the iTerra team as advisors.

iTerra is collaborating with leading U.S. agricultural universities and USDA research partners UC Davis, Cornell and Rutgers to validate initial positive test results at scale in diverse climates and with different soil types across seasonal changes. Large parcel testing, essential to fully prove commercial viability and scalability, is expected to commence in the second quarter of 2026. Initial research conducted at l’École d’Ingénieurs de Purpan in Toulouse, France, confirmed the company’s results showing that iTerra technology does not disturb soil microbiology and has high weed-control efficiency.

iTerra CEO Romain Leray commented: “This is a completely new approach to weed control. At iTerra, we’re combining two advanced technologies - high pulsed power and AI - to give farmers the ability to produce healthy organic food with absolutely no chemical herbicides involved.”

Farmers worldwide have relied on chemical herbicides to meet the pressures of feeding a rapidly growing population. Yet these products accumulate in soil, water and food chains, raising environmental and health concerns and impacting ecosystems. At the same time, many weed species have developed resistance to common herbicides, forcing growers to increase application rates to maintain effectiveness. With farm margins tightening, few economically viable alternatives available, and herbicide regulations becoming increasingly restrictive, iTerra aims to provide farmers facing mounting pressure with a new more effective, more sustainable solution.

Learn more and watch iTerra in action at:
https://www.ipulse-group.com/our-businesses/iterra/

ABOUT I-PULSE

I-Pulse is a private American company co-founded by Robert Friedland and Laurent Frescaline to bring high pulsed power technology into civilian sectors. I-Pulse technology – which repeatedly compresses and releases brief yet immensely powerful electrical discharges – holds the potential to address critical global issues like the unlocking of competitive geothermal base-load energy sources, agricultural crop protection, efficient critical mineral production, and disruptive welding, metal-forming and crimping solutions at industrial scale. Founded in 2007, I-Pulse has offices in New York and London and lab and manufacturing facilities in Albuquerque, New Mexico, Detroit, Michigan and Toulouse, France.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311080724/en/

Contacts

Follow @I-Pulse Group on LinkedIn & Robert Friedland @robert_ivanhoe on X.
For Media: Ross Larsen, I-PulseCommunications@ipulse-group.com
For Investors: Abby Symes, Contact@ipulse-group.com
Website www.ipulse-group.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ipulse-grou
p.com&esheet=54444294&newsitemid=20260311080724&lan=en-US&anchor=www.ipulse-grou
p.com&index=2&md5=ec0c3d967d65636e1e6dfa5a8a20a3f5

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press Release

A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press Release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press Release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press Release

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye